Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia

NCT01164059 is registered in ClinicalTrials.gov with University of Bremen as lead sponsor.

NCT NCT01164059
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01164059 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia
Lead sponsor
University of Bremen
Phase
Phase 4
Overall status
Completed
Start date
February 28, 2010
Completion date
March 31, 2014
Enrollment
149 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia